Litaba tsa mohala

Phekolo e Ncha ea Kopo ea Lithethefatsi ea Lihlahala tse Tsoetseng Pele tse Tiileng

ngotsoeng ke mohlophisi

Kajeno Nuvation Bio Inc. e phatlalalitse hore US Food and Drug Administration (FDA) e hlakotse kopo ea eona ea setlhare se secha sa lipatlisiso (IND) ho hlahloba NUV-868, BD2-selective oral small molecule bromodomain le extra-terminal (BET) inhibitor, bakeng sa kalafo ea lihlahala tse tiileng tse tsoetseng pele, ho kenyeletsoa mofets'e oa mahe a bomme, mofets'e oa pancreatic, mofets'e oa tšoelesa ea senya ea metastatic castration (mCRPC), le mofetše oa matsoele o mpe ka makhetlo a mararo (TNBC).

"Ho hlakoloa ha kopo ea rona ea IND bakeng sa NUV-868 ke mohato oa bohlokoa bakeng sa Nuvation Bio kaha e tšoaea IND ea bone likhoeling tse 14 tse fetileng ho phaephe ea rona e tebileng ea kalafo ea mofets'e e shebaneng le mefuta e mengata ea lihlahala," ho boletse David Hung, MD, mothehi. , mopresidente, le ofisiri e ka sehloohong ea Nuvation Bio. "Re khothatsoa ke boikhethelo le mamello e ntlafalitsoeng e bonts'itsoeng ke NUV-868 lithutong tsa pele, 'me re lebelletse ho ntšetsa pele lenaneo ho nts'etsopele ea Mokhahlelo oa 1 bohareng ba 2022."

NUV-868 e thibela BRD4, e leng setho sa bohlokoa sa lelapa la BET le laolang liprotheine tse laolang kholo ea hlahala le ho arohana. NUV-868 e etselitsoe ho khetha haholo bakeng sa BD2 ho feta BD1 molemong oa ho qoba chefo e fokotsang kalafo ea li-inhibitor tse ling tsa BRD4 joalo ka gastrointestinal (GI) le chefo ea moko oa masapo. Boithuto ba preclinical bo bonts'itse NUV-868 e batla e khetha makhetlo a 1,500 bakeng sa BD2 ho feta BD1. Li-inhibitor tse sa khethoeng tsa BD1/2 tse nts'etsopele li 'nile tsa amahanngoa le mathata a mamello, mohlomong ka lebaka la thibelo e ngata ea BD1.

Ka ho hlakoloa ha IND ena bakeng sa NUV-868 ka lihlahala tse tiileng tse tsoetseng pele, Nuvation Bio e tla be e qala thuto ea Phase 1/2 ea NUV-868 e le monotherapy 'me e kopane le olaparib kapa enzalutamide mefuteng e mengata ea hlahala. Protocol ena (NUV-868-01) e tla qala ka thuto ea phallo ea lethal dose ea 1 ho bakuli ba tsoetseng pele ba tiileng ba tumor. Thuto ea Phase 1b e tla qalisoa ho hlahloba NUV-868 hammoho le olaparib ho mofetše oa mahe a bomme, kankere ea pancreatic, mCRPC, le bakuli ba TNBC hammoho le enzalutamide bakeng sa bakuli ba mCRPC e lateloang ke thuto ea Phase 2b ho tsoela pele ho hlahloba polokeho le katleho. hang ha tekanyetso ea motsoako oa Phase 2 e khothalelitsoe. Boithuto ba Mokhahlelo oa 2 ba monotherapy le bona bo tla qalisoa ho bakuli ba mCRPC le ho tsoela pele ho hlahloba polokeho le katleho.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Subscribe
Tsebiso ea
moeti
0 Comments
Li-feed tsa marang-rang
Sheba maikutlo ohle
0
Ke rata maikutlo a hau, ka kopo fana ka maikutlo.x
()
x
Arolelana ho...